# Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support

Study · id `cardio:ct-nct05594342` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05594342](<https://clinicaltrials.gov/study/NCT05594342>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05594342

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05594342. Randomized; no masking; primary purpose treatment. Start 2022-07-01 (actual); primary completion 2023-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05594342, source copy `cardio:ctgov-nct05594342-2022-10-26`, retrieved 2026-10-26)
- Started: 2022-07-01 (actual) (ClinicalTrials.gov record NCT05594342, source copy `cardio:ctgov-nct05594342-2022-10-26`, retrieved 2026-10-26)
- Primary completion: 2023-01-01 (anticipated) (ClinicalTrials.gov record NCT05594342, source copy `cardio:ctgov-nct05594342-2022-10-26`, retrieved 2026-10-26)
- Completion: 2023-01-01 (anticipated) (ClinicalTrials.gov record NCT05594342, source copy `cardio:ctgov-nct05594342-2022-10-26`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05594342, source copy `cardio:ctgov-nct05594342-2022-10-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05594342-2022-10-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
- Acronym: IVA-CS
- Condition: Heart Failure
- Condition: Cardiogenic Shock
- Condition: Ischemic Heart Disease
- Intervention (Drug): Ivabradine 7.5Mg Tab
- Intervention (Drug): DOBUTamine Injectable Solution
- Lead sponsor: The Young Investigator Group of Cardiovascular Research
- Lead sponsor class: NETWORK

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: f4dd73cf40468fc84a1a0efecb59e904eaed91b4f761a5aedbcd090813594629
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
